Litcius/Paper detail

Efficacy and safety of once-daily nitisinone for patients with alkaptonuria (SONIA 2): an international, multicentre, open-label, randomised controlled trial

L. Ranganath, Eftychia Eirini Psarelli, Jean-Baptiste Arnoux, Daniela Braconi, Michael Briggs, Anders Bröijersén, Nadia Loftus, Helen Bygott, Trevor F. Cox, Andrew Davison, J.P. Dillon, Michael Fisher, Richard J. Fitzgerald, Federica Genovese, Helena Glasová, Anthony K Hall, Andrew T. Hughes, Juliette H. Hughes, Richard Imrich, Jonathan C. Jarvis, Milad Khedr, Dinny Laan, Kim‐Hanh Le Quan Sang, Emily Luangrath, Oľga Lukáčová, Anna M. Milan, Alpesh Mistry, Vanda Mlynáriková, Brendan P. Norman, Birgitta Olsson, Nicholas P Rhodes, Jozef Rovenský, Mattias Rudebeck, Annalisa Santucci, Ella Shweihdi, Ciarán Scott, Jana Sedláková, Nicolas Sireau, Roman Stančík, Johan Szamosi, Sophie Taylor, Christa van Kan, Sobhan Vinjamuri, Eva Vrtíková, Chris Webb, Elizabeth A. West, E. Záňová, Andrea Zaťková, James A. Gallagher

2020The Lancet Diabetes & Endocrinology124 citationsDOIOpen Access PDF

Topics & Concepts

AlkaptonuriaMedicineHomogentisic acidRandomized controlled trialClinical endpointInternal medicineClinical trialUrinary systemAdverse effectPhysical therapyPediatricsSurgeryDermatologyChemistryBiochemistryMetabolism and Genetic DisordersAdrenal Hormones and DisordersBlood disorders and treatments
Efficacy and safety of once-daily nitisinone for patients with alkaptonuria (SONIA 2): an international, multicentre, open-label, randomised controlled trial | Litcius